ADT for Prostate Cancer May Increase Cataract Risk

Share this article:

Androgen deprivation therapy (ADT) may increase the risk of cataracts among men with prostate cancer (PCa), according to the findings of a large study.

ADT can cause weight gain, dyslipidemia, and insulin resistance. These metabolic abnormalities also have been linked with cataracts, leading researchers to question whether this ophthalmologic condition could be another adverse consequence of ADT use. Jennifer Beebe-Dimmer, PhD, of the Karmanos Cancer Institute in Detroit, and colleagues used the Surveillance, Epidemiology and End Results (SEER) database to estimate cataract risk associated with ADT among 65,852 men with PCa who had received such therapy (at least one dose of a gonadotropin-releasing hormone agonist or orchiectomy) within six months after being diagnosed.

After comparing outcomes with men not treated with ADT, the investigators found that gonadotropin-releasing hormone agonist use was associated with a 9% increase in cataract incidence, which they described as “modest” in an online report in Annals of Epidemiology. A 26% increase in cataract incidence was noted among men who had no history of cataracts prior to undergoing orchiectomy.

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Prostate Cancer

More in Prostate Cancer

Blacks with Recurrent Prostate Cancer More Likely To Regret Treatment

Blacks with Recurrent Prostate Cancer More Likely To ...

Racial differences in prostate cancer (PCa) treatment regret more pronounced among those without sexual problems.

Androgen Deprivation Therapy (ADT) Raises Heart-Related Death Risk

Androgen Deprivation Therapy (ADT) Raises Heart-Related Death Risk

But overall risk of heart-related death risk from prostate cancer treatment is small, researchers say.

Men with More Female Partners Have Lower Prostate Cancer (PCa) Risk

Men with More Female Partners Have Lower Prostate ...

Men who have slept with more than 20 female partners are less likely to develop aggressive prostate cancer (PCa).